Business Wire

OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, Its Second Generation COVID-19 Vaccine

In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR) in monotherapy and in combination with checkpoint inhibitor Opdivo ®. CoVepiT: a prophylactic vaccine against COVID-19, developed using ...
Business Wire

OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT

OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) today announced the online publication in BioRxiv of positive data from preclinical and human ex vivo studies with CoVepiT, its ...